Overview

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Pfizer
Treatments:
Apixaban
Atenolol